21 citations
,
August 1987 in “Archives of Dermatology” High-dose methotrexate can cause severe skin and nail issues.
September 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” FOL-026 peptide can help repair blood vessels and promote growth, offering potential treatment for vascular diseases.
11 citations
,
January 2014 in “The Scientific World Journal” Cynatine HNS improves hair and nail quality in 90 days.
49 citations
,
December 1997 in “Urology” Tamoxifen effectively treats gynecomastia without causing impotence.
1 citations
,
April 2024 in “Anais Brasileiros de Dermatologia”
9 citations
,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
September 2020 in “Acta Scientific Cancer Biology” Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.
5 citations
,
October 2023 in “Phytotherapy Research” Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
April 2018 in “Journal of Investigative Dermatology” NDRG1 protein helps infantile hemangioma, a common infant tumor, to grow, and its mismanagement by FOXO1 protein plays a big role in causing the tumor.
36 citations
,
January 1991 in “PubMed” 2% Minoxidil does not prevent hair loss during chemotherapy.
September 2025 in “Value in Health”
20 citations
,
May 2011 in “Cancer Biology & Therapy” Finasteride may improve prostate cancer treatment outcomes.
6 citations
,
August 2020 in “Oncology nursing forum” Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
11 citations
,
June 1996 in “Nutrition” Vitamin D3 may prevent hair loss from chemotherapy, but side effects and cancer cell protection are concerns.
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
August 2016 in “PolyPublie (École Polytechnique de Montréal)” Doxorubicin causes heart damage, so early detection and monitoring are important during chemotherapy.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
1 citations
,
November 2023 in “BMC chemistry” Tadalafil and Finasteride may help treat aggressive melanoma.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
2 citations
,
May 1991 in “PubMed” Nevus comedonicus is a rare skin condition causing dark bumps, treatable with retinoic acid or surgery.
2 citations
,
November 2019 in “Skin appendage disorders” Platelet-rich plasma doesn't prevent hair loss from chemotherapy, and mononuclear cells only help against hair loss from one specific chemotherapy drug.
Different oral anticoagulants cause various non-bleeding side effects, so careful monitoring is needed.
12 citations
,
October 2020 in “Scientific Reports” Necrostatin-1s can promote hair growth and may help treat hair loss.
October 2007 in “Clinical Biochemistry” New genotype linked to non-classical congenital adrenal hyperplasia found in Italian siblings.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
April 2018 in “Journal of Investigative Dermatology” The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.